Artificial intelligence is becoming more relevant in pharmaceutical research and development and diagnostic medicine, owing to its ability to analyze high quantities of data with precision rates matching and, in many cases, exceeding those of its human competitors in those fields.
GOT Law Associate Ty Feeney, along with co-author Dr. Michael Sinha of the Saint Louis University School of Law, provide their analysis of a selection of studies regarding groundbreaking applications of AI in the pharmaceutical and medical fields in their new article A.I. Renaissance: Pharmaceuticals and Diagnostic Medicine. Feeney and Sinha also suggest a novel framework for the regulation of AI in the healthcare industry and, more broadly, throughout American industries as a whole.
See Ty’s article here.